Table 2.
Multivariate overall survival (OS) analysis among patients who received trimodality therapy (TMT) for muscle invasive bladder.
| Variable | Level | N | Hazard Ratio (95% CI) | P-value* |
|---|---|---|---|---|
|
| ||||
| Cohort | TMT | 2108 | - | |
| NAC+TMT | 463 | 1.01 (0.88–1.15) | 0.921 | |
| Age at Diagnosis | <60 | 192 | - | - |
| 60–69 | 456 | 1.30 (1.02–1.66) | 0.035 | |
| 70–79 | 857 | 1.75 (1.38–2.23) | <0.001 | |
| 80+ | 1040 | 2.13 (1.67–2.70) | <0.001 | |
| Race | White | 2270 | - | - |
| Black | 155 | 1.17 (0.95–1.43) | 0.132 | |
| Asian-Indian-Pacific | 39 | 0.66 (0.42–1.04) | 0.075 | |
| Hispanic | 51 | 0.76 (0.51–1.12) | 0.165 | |
| Other/unknown | 30 | 1.12 (0.80–1.83) | 0.372 | |
| Year | 2004–2006 | 522 | - | - |
| 2007–2009 | 615 | 1.13 (0.99–1.29) | 0.074 | |
| 2010–2012 | 567 | 1.06 (0.92–1.22) | 0.395 | |
| 2013–2015 | 841 | 1.16 (1.01–1.34) | 0.037 | |
| Charlson-Deyo Score | 0 | 1624 | - | - |
| 1+ | 921 | 1.27 (1.15–1.40) | <0.001 | |
| Clinical T stage | T2 | 2099 | - | - |
| T3–4 | 446 | 1.43 (1.27–1.61) | <0.001 | |
| Insurance | Private | 435 | - | - |
| Medicare | 1933 | 1.14 (0.98–1.32) | 0.079 | |
| Other | 177 | 1.34 (1.07–1.68) | 0.010 | |
| Median income | >=$63,000 | 782 | - | - |
| < $38,000 | 402 | 0.92 (0.76–1.12) | 0.423 | |
| $38,000–$47,999 | 632 | 1.10 (0.94–1.28) | 0.248 | |
| $48,000–$62,999 | 738 | 0.96 (0.83–1.10) | 0.523 | |
| No high school degree (%) | <7.0% | 621 | - | - |
| 7.0–12.9% | 939 | 1.06 (0.92–1.22) | 0.441 | |
| 13.0–20.9% | 630 | 1.12 (1.02–1.44) | 0.025 | |
| ≥21.0% | 365 | 1.12 (0.91–1.37) | 0.293 | |
| Region | West | 409 | - | - |
| Northeast | 623 | 0.90 (0.77–1.06) | 0.206 | |
| South | 799 | 0.97 (0.83–1.14) | 0.732 | |
| Midwest | 714 | 1.14 (0.98–1.33) | 0.087 | |
Abbreviation: CI, confidence interval